Manulife (Manufacturers Life Insurance)
MYGN icon

Manulife (Manufacturers Life Insurance)’s Myriad Genetics MYGN Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113K Sell
25,150
-2,345
-9% -$12.2K ﹤0.01% 2597
2025
Q4 		$169K Sell
27,495
-3,261
-11% -$23.6K ﹤0.01% 2590
2025
Q3 		$222K Sell
30,756
-14,556
-32% -$86.4K ﹤0.01% 2521
2025
Q2 		$241K Buy
45,312
+13
+0% +$77 ﹤0.01% 2474
2025
Q1 		$402K Buy
45,299
+1,319
+3% +$15.8K ﹤0.01% 2242
2024
Q4 		$603K Sell
43,980
-5,268
-11% -$97.2K ﹤0.01% 2142
2024
Q3 		$1.35M Sell
49,248
-823
-2% -$22.3K ﹤0.01% 1762
2024
Q2 		$1.22M Buy
50,071
+4,528
+10% +$99.4K ﹤0.01% 1747
2024
Q1 		$971K Buy
45,543
+4,426
+11% +$95.1K ﹤0.01% 1871
2023
Q4 		$787K Buy
41,117
+126
+0.3% +$2.18K ﹤0.01% 1940
2023
Q3 		$657K Buy
40,991
+8,374
+26% +$159K ﹤0.01% 1996
2023
Q2 		$756K Buy
32,617
+556
+2% +$12.1K ﹤0.01% 1799
2023
Q1 		$745K Buy
32,061
+134
+0.4% +$2.72K ﹤0.01% 1766
2022
Q4 		$463K Buy
31,927
+172
+0.5% +$3.21K ﹤0.01% 2042
2022
Q3 		$606K Sell
31,755
-658
-2% -$15.1K ﹤0.01% 1854
2022
Q2 		$589K Sell
32,413
-485
-1% -$10.1K ﹤0.01% 1935
2022
Q1 		$829K Sell
32,898
-7,180
-18% -$184K ﹤0.01% 1861
2021
Q4 		$1.11K Sell
40,078
-125
-0.3% -$3.62K ﹤0.01% 1768
2021
Q3 		$1.3M Sell
40,203
-3,036
-7% -$101K ﹤0.01% 1677
2021
Q2 		$1.32M Buy
43,239
+2,991
+7% +$86.4K ﹤0.01% 1823
2021
Q1 		$1.23M Sell
40,248
-2,842
-7% -$80.7K ﹤0.01% 1783
2020
Q4 		$852K Buy
43,090
+1,162
+3% +$18.8K ﹤0.01% 1908
2020
Q3 		$547K Sell
41,928
-859
-2% -$10.9K ﹤0.01% 1959
2020
Q2 		$472K Sell
42,787
-2,433
-5% -$34.5K ﹤0.01% 1992
2020
Q1 		$647K Buy
45,220
+3,215
+8% +$67.9K ﹤0.01% 1712
2019
Q4 		$1.14M Sell
42,005
-1,212
-3% -$33.3K ﹤0.01% 1610
2019
Q3 		$1.23M Sell
43,217
-470
-1% -$13.7K ﹤0.01% 1553
2019
Q2 		$1.21M Sell
43,687
-1,244
-3% -$35.1K ﹤0.01% 1557
2019
Q1 		$1.49M Buy
44,931
+3,457
+8% +$105K ﹤0.01% 1509
2018
Q4 		$1.21M Sell
41,474
-1,544
-4% -$55.5K ﹤0.01% 1520
2018
Q3 		$1.98M Sell
43,018
-5,369
-11% -$239K ﹤0.01% 1465
2018
Q2 		$1.81M Sell
48,387
-3
-0% -$101 ﹤0.01% 1533
2018
Q1 		$1.43M Sell
48,390
-1,123
-2% -$38K ﹤0.01% 1638
2017
Q4 		$1.7M Buy
49,513
+832
+2% +$28.1K ﹤0.01% 1560
2017
Q3 		$1.76M Sell
48,681
-1,195
-2% -$34.1K ﹤0.01% 1498
2017
Q2 		$1.29M Sell
49,876
-2,773
-5% -$58.9K ﹤0.01% 1655
2017
Q1 		$1.01M Buy
52,649
+6,448
+14% +$114K ﹤0.01% 1730
2016
Q4 		$770K Buy
46,201
+323
+0.7% +$5.84K ﹤0.01% 1809
2016
Q3 		$944K Sell
45,878
-374,574
-89% -$9.5M ﹤0.01% 1678
2016
Q2 		$12.9M Sell
420,452
-7,298
-2% -$254K 0.02% 581
2016
Q1 		$15.9M Buy
427,750
+10,109
+2% +$381K 0.01% 511
2015
Q4 		$18K Buy
417,641
+113,755
+37% +$4.81M 0.02% 477
2015
Q3 		$11.4K Sell
303,886
-802,191
-73% -$28.5M 0.01% 612
2015
Q2 		$37.6K Sell
1,106,077
-30,575
-3% -$1.04M 0.04% 303
2015
Q1 		$40.2K Buy
1,136,652
+198,425
+21% +$7.1M 0.05% 267
2014
Q4 		$32K Sell
938,227
-85,694
-8% -$3.04M 0.05% 303
2014
Q3 		$39.5K Sell
1,023,921
-452,254
-31% -$16.9M 0.06% 256
2014
Q2 		$57.5M Buy
1,476,175
+1,472,153
+36,603% +$54.8M 0.09% 193
2014
Q1 		$137 Buy
4,022
+1,678
+72% +$52K ﹤0.01% 2933
2013
Q4 		$49 Sell
2,344
-3,572
-60% -$90.3K ﹤0.01% 3209
2013
Q3 		$139 Sell
5,916
-1,958
-25% -$55.6K ﹤0.01% 2907
2013
Q2 		$212K Buy
+7,874
New +$228K ﹤0.01% 2525

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s MYGN Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Myriad Genetics (MYGN) stake by 8.5% in Q1 2026, selling an estimated $12.2K and leaving 25,150 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #2597.

Manulife (Manufacturers Life Insurance) first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $57.5M in Q2 2014. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 25,150 shares of Myriad Genetics worth $113K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 2,345 Myriad Genetics shares in Q1 2026, an estimated $12.2K.
  • Myriad Genetics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2597 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Myriad Genetics position peaked at $57.5M in Q2 2014.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.